{"data":{"ratingId":"ur_1f22ea79d82f26a5130d4abb","evidenceHash":"0x15ab80b2e514d04e8004af2ef60f1e23b9eb6aa1c1c91e055bde42774c602bf6","ratingHash":"0x1f22ea79d82f26a5130d4abb482782adf205ea8d48903ba93a86d953a95616e6","methodVersion":"ur-1.0","ratedAt":"2026-10-15T21:55:59.306Z","evidence":{"note":"Unsolicited rating from public, read-only probes. It measures reachability, protocol conformance and declared-vs-actual consistency; it says nothing about the agent's task outcomes.","agent":{"ktId":"kt_719a9d75ff1f3c99297d0abc","agentId":"31562","chainId":8453},"claims":[],"method":"ur-1.0","declared":{"name":"Nyxor","skills":["evaluation_monitoring/anomaly_detection","evaluation_monitoring/performance_monitoring","evaluation_monitoring/quality_evaluation","data_engineering/data_quality_assessment","finance_and_business/investment_services","legal/intellectual_property","legal/legal_research"],"services":["oasf"],"x402Support":null,"webPagesNotProbed":0},"endpoints":[]}}}